Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Measuring circulating complement activation products in myeloperoxidase and proteinase 3 antineutrophil cytoplasmic antibody vasculitis.

Wu EY, McInnis EA, Boyer-Suavet S, Mendoza CE, Aybar LT, Kennedy KB, Poulton CJ, Henderson CD, Hu Y, Hogan SL, Hu P, Xiao H, Nachman PH, Jennette JC, Falk RJ, Bunch DO.

Arthritis Rheumatol. 2019 Jun 19. doi: 10.1002/art.41011. [Epub ahead of print]

PMID:
31215772
2.

Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Hogan SL, Nachman PH, Poulton CJ, Hu Y, Blazek LN, Free ME, Jennette JC, Falk RJ.

Kidney Int Rep. 2019 Jan 28;4(4):551-560. doi: 10.1016/j.ekir.2019.01.004. eCollection 2019 Apr.

3.

Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity.

Lardinois OM, Deterding LJ, Hess JJ, Poulton CJ, Henderson CD, Jennette JC, Nachman PH, Falk RJ.

PLoS One. 2019 Feb 28;14(2):e0213215. doi: 10.1371/journal.pone.0213215. eCollection 2019.

4.

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.

Chanouzas D, McGregor JAG, Nightingale P, Salama AD, Szpirt WM, Basu N, Morgan MD, Poulton CJ, Draibe JB, Krarup E, Dospinescu P, Dale JA, Pendergraft WF, Lee K, Egfjord M, Hogan SL, Harper L.

BMC Nephrol. 2019 Feb 18;20(1):58. doi: 10.1186/s12882-019-1226-0.

5.

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium.

Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9.

PMID:
30420158
6.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):301-308. doi: 10.1093/ndt/gfy106.

7.

Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, Wolterbeek R, Nguyen TQ, Goldschmeding R, Alchi B, Griffiths M, de Zoysa JR, Vincent B, Bruijn JA, Bajema IM.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72. doi: 10.2215/CJN.04290417. Epub 2017 Nov 21.

8.

Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015.

O'Shaughnessy MM, Hogan SL, Poulton CJ, Falk RJ, Singh HK, Nickeleit V, Jennette JC.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):614-623. doi: 10.2215/CJN.10871016. Epub 2017 Mar 21.

9.

Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.

Payan Schober F, Jobson MA, Poulton CJ, Singh HK, Nickeleit V, Falk RJ, Jennette JC, Nachman PH, Pendergraft Iii WF.

Am J Nephrol. 2017;45(3):248-256. doi: 10.1159/000455390. Epub 2017 Feb 4.

10.

Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis.

Jones BE, Yang J, Muthigi A, Hogan SL, Hu Y, Starmer J, Henderson CD, Poulton CJ, Brant EJ, Pendergraft WF 3rd, Jennette JC, Falk RJ, Ciavatta DJ.

J Am Soc Nephrol. 2017 Apr;28(4):1175-1187. doi: 10.1681/ASN.2016050548. Epub 2016 Nov 7.

11.

Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Yang J, Ge H, Poulton CJ, Hogan SL, Hu Y, Jones BE, Henderson CD, McInnis EA, Pendergraft WF 3rd, Jennette JC, Falk RJ, Ciavatta DJ.

Clin Epigenetics. 2016 Aug 12;8:85. doi: 10.1186/s13148-016-0251-0. eCollection 2016.

12.

Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.

Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1752-1759. doi: 10.2215/CJN.13091215. Epub 2016 Jul 21.

13.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

PMID:
26924046
14.

Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):386-94. doi: 10.2215/CJN.07110615. Epub 2016 Feb 16.

15.

Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.

Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, Merkel PA.

Arthritis Rheumatol. 2016 Jul;68(7):1711-20. doi: 10.1002/art.39614.

16.

Patient-Reported Outcome Instruments for Physical Symptoms Among Patients Receiving Maintenance Dialysis: A Systematic Review.

Flythe JE, Powell JD, Poulton CJ, Westreich KD, Handler L, Reeve BB, Carey TS.

Am J Kidney Dis. 2015 Dec;66(6):1033-46. doi: 10.1053/j.ajkd.2015.05.020. Epub 2015 Jul 23. Review.

17.

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JG.

Ann Rheum Dis. 2015 Sep;74(9):1784-6. doi: 10.1136/annrheumdis-2014-206756. Epub 2015 Apr 30. No abstract available.

18.

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.

McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i171-81. doi: 10.1093/ndt/gfv045.

19.

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.

McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i123-31. doi: 10.1093/ndt/gfv076.

20.

What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population.

Berg EA, McGregor JG, Burkart ME, Poulton CJ, Hu Y, Falk RJ, Hogan SL.

J Autoimmune Dis Rheumatol. 2014 Nov 1;2(3):74-91.

21.

PTPN22 R620W polymorphism and ANCA disease risk in white populations: a metaanalysis.

Cao Y, Liu K, Tian Z, Hogan SL, Yang J, Poulton CJ, Falk RJ, Li W.

J Rheumatol. 2015 Feb;42(2):292-9. doi: 10.3899/jrheum.131430. Epub 2014 Dec 1.

22.

Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.

Aybar LT, McGregor JG, Hogan SL, Hu Y, Mendoza CE, Brant EJ, Poulton CJ, Henderson CD, Falk RJ, Bunch DO.

Clin Exp Immunol. 2015 May;180(2):178-88. doi: 10.1111/cei.12483.

23.

Severe presentation of WDR62 mutation: is there a role for modifying genetic factors?

Poulton CJ, Schot R, Seufert K, Lequin MH, Accogli A, Annunzio GD, Villard L, Philip N, de Coo R, Catsman-Berrevoets C, Grasshoff U, Kattentidt-Mouravieva A, Calf H, de Vreugt-Gronloh E, van Unen L, Verheijen FW, Galjart N, Morris-Rosendahl DJ, Mancini GM.

Am J Med Genet A. 2014 Sep;164A(9):2161-71. doi: 10.1002/ajmg.a.36611. Epub 2014 May 19.

PMID:
24842779
24.

Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2014 May;9(5):905-13. doi: 10.2215/CJN.08290813. Epub 2014 Feb 27.

25.

Podocyte-associated gene mutation screening in a heterogeneous cohort of patients with sporadic focal segmental glomerulosclerosis.

Laurin LP, Lu M, Mottl AK, Blyth ER, Poulton CJ, Weck KE.

Nephrol Dial Transplant. 2014 Nov;29(11):2062-9. doi: 10.1093/ndt/gft532. Epub 2014 Feb 4.

PMID:
24500309
26.

Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.

Geetha D, Poulton CJ, Hu Y, Seo P, McGregor JA, Falk RJ, Hogan SL.

Semin Arthritis Rheum. 2014 Jun;43(6):778-83. doi: 10.1016/j.semarthrit.2013.11.011. Epub 2013 Dec 4.

27.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

28.

A single strand that links multiple neuropathologies in human disease.

Oegema R, Poulton CJ, Mancini GM.

Brain. 2014 Apr;137(Pt 4):e266. doi: 10.1093/brain/awt197. Epub 2013 Aug 5. No abstract available.

PMID:
23921166
29.

Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis.

Poulton CJ, Nachman PH, Hu Y, McGregor JG, Jennette JC, Falk RJ, Hogan SL.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S32-7. Epub 2013 Jan 23.

30.

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2013 Mar;8(3):382-91. doi: 10.2215/CJN.03950412. Epub 2013 Jan 4.

31.

RTTN mutations link primary cilia function to organization of the human cerebral cortex.

Kheradmand Kia S, Verbeek E, Engelen E, Schot R, Poot RA, de Coo IF, Lequin MH, Poulton CJ, Pourfarzad F, Grosveld FG, Brehm A, de Wit MC, Oegema R, Dobyns WB, Verheijen FW, Mancini GM.

Am J Hum Genet. 2012 Sep 7;91(3):533-40. doi: 10.1016/j.ajhg.2012.07.008. Epub 2012 Aug 30.

32.

COL4A2 mutation associated with familial porencephaly and small-vessel disease.

Verbeek E, Meuwissen ME, Verheijen FW, Govaert PP, Licht DJ, Kuo DS, Poulton CJ, Schot R, Lequin MH, Dudink J, Halley DJ, de Coo RI, den Hollander JC, Oegema R, Gould DB, Mancini GM.

Eur J Hum Genet. 2012 Aug;20(8):844-51. doi: 10.1038/ejhg.2012.20. Epub 2012 Feb 15.

33.

Microcephaly with simplified gyration, epilepsy, and infantile diabetes linked to inappropriate apoptosis of neural progenitors.

Poulton CJ, Schot R, Kia SK, Jones M, Verheijen FW, Venselaar H, de Wit MC, de Graaff E, Bertoli-Avella AM, Mancini GM.

Am J Hum Genet. 2011 Aug 12;89(2):265-76. doi: 10.1016/j.ajhg.2011.07.006.

Supplemental Content

Loading ...
Support Center